Rational conversion of biologically active peptides to nonpeptide compounds with retained activity is an appealing approach in drug development. One important objective of the work presented in this thesis was to use computational modeling to aid in such a conversion of the peptide angiotensin II (Ang II, Asp-Arg-Val-Tyr-Ile-His-Pro-Phe). An equally important objective was to gain an understanding of the requirements for ligand binding to the Ang II receptors, with a focus on interactions with the AT2 receptor. The bioactive conformation of a peptide can provide important guidance in peptidomimetic design. By designing and introducing well-defined secondary structure mimetics into Ang II the bioactive conformation can be addressed. In this work, both γ- and β-turn mimetic scaffolds have been designed and characterized for incorporation into Ang II. Using conformational analysis and the pharmacophore recognition method DISCO, a model was derived of the binding mode of the pseudopeptide Ang II analogues. This model indicated that the positioning of the Arg side chain was important for AT2 receptor binding, which was also supported when the structure–activity relationship of Ang II was investigated by performing a glycine scan. To further examine ligand binding, a 3D model of the AT2 receptor was constructed employing homology modeling. Using this receptor model in a docking study of the ligands, binding modes were identified that were in agreement with data from point-mutation studies of the AT2 receptor. By investigating truncated Ang II analogues, small pseudopeptides were developed that were structurally similar to nonpeptide AT2 receptor ligands. For further guidance in ligand design of nonpeptide compounds, three-dimensional quantitative structure–activity relationship models for AT1 and AT2 receptor affinity as well as selectivity were derived.

No description available.

A hipótese do estudo é a de que a Angiotensina II (AngII) é capaz de desencadear processos inflamatórios iniciais que compõem parte dos mecanismos envolvidos na lesão vascular ou no seu progresso. Os objetivos foram avaliar a expressão de marcadores iniciais de inflamação em resposta à ação da AngII e por qual receptor (AT1 ou AT2) esta levaria à expressão destes marcadores inflamatórios. O estudo foi realizado em camundongos machos C57Bl/6J submetidos ao tratamento com doses subpressoras de AngII, bloqueadores dos receptores AT1 e AT2 e uma combinação destes. Os tempos de tratamento foram determinados através de uma curva de tempo-resposta feita com injeções de AngII. Após definição da curva temporal foram preparados 6 grupos de animais: controle, tratados AngII, Losartan, AngII+Losartan, PD123319 e AngII+PD123319. Foram feitas avaliações dos marcadores inflamatórios nos corações por imunohistoquímica para citocinas IL-1<font face=\"Symbol\">b e IL-6, TNF<font face=\"Symbol\">a, TGF-<font face=\"Symbol\">b e MCP-1, a molécula de adesão ICAM-1, e foram quantificados a IL-6 e o TNF-<font face=\"Symbol\">a séricos pela técnica ELISA. / The study hypothesis is that the angiotensin II (Ang II) is capable of triggering inflammatory processes that comprise the initial part of the mechanisms involved in vascular injury or in progress. The objectives were to evaluate the expression of early markers of inflammation in response to the action of Ang II and which receptor (AT1 and AT2) this would lead to the expression of these inflammatory markers. The study was conducted in male C57Bl/6J mice undergoing treatment with subpressor doses of AngII, blockers of AT1 and AT2 receptors and a combination thereof. Treatment times were determined using a time-response curve performed with injections of AngII. After definition of time curve were prepared six animal groups: control, treated Ang II, losartan, Ang II + losartan, PD123319 and Ang II + PD123319. Evaluations were made in the hearts of inflammatory markers by immunohistochemistry for IL-1<font face=\"Symbol\">b and IL-6, TNF<font face=\"Symbol\">a, TGF-<font face=\"Symbol\">b and MCP-1, the adhesion TNF-<font face=\"Symbol\">a serum by ELISA.

L'objectif de ce travail était de développer de nouvelles voies d'obtention de produits acides potentiellement ligand du zinc dans le cadre d'un projet plus vaste mené au laboratoire sur deux cibles biologiques appartenant à la famille des métalloprotéases à zinc, l'aggrécanase et l'enzyme de conversion de l'angiotensine de type 2.<br />La stratégie chimique utilisée a été la phase solide à l'aide d'une résine chlorure de trityle. La synthèse a été effectuée à partir de dérivés amino-acide protégés par un carbamate de fluorénylméthyle ou d'éthylène-oxy-triméthyle silicium permettant une déprotection en parallèle de la fonction amine une fois la fonction acide fixée à la résine. Nous avons obtenu une chimiothèque de 400 composés. A partir de ces 400 produits un hit a été identifié comme inhibiteur potentiel de l'aggrécanase 2. Des études de relations structures activités d'analogues de ce hit sont actuellement en cours.<br />En parallèle, comme le tétrazole fait partie des fonctions chimiques potentiellement ligand du zinc et est une fonction phare dans le développement d'inhibiteurs du récepteur à l'angiotensine 2 (AT1), nous avons développé une nouvelle technique de greffage de tétrazole sur résine et de synthèse de chimiothèque biphényltétrazole.Ces travaux ont permis la mise au point d'une nouvelle méthode de synthèse de biphényltétrazole en phase homogène au micro-onde et la synthèse innovante de dérivés biphényltétrazole en phase solide exemplifié par la synthèse de l'irbésartan en phase solide.<br />Nous avons ensuite développé des dérivés biphényltétrazole pyrazole. Pour cette famille de molécules, nous avons exploité les études effectuées sur la réaction de Buchwald que nous avons adaptée à nos composés. De plus ces mêmes travaux ont permis la mise au point d'une nouvelle réaction d'obtention de dérivés para-iodophényle pyrazole en une seule étape et qui ouvre une nouvelle voie rétrosynthétique de dérivés phényle pyrazole. Cinq de ces produits ont montré sur activité sur le récepteur AT1.

Many peptide receptors are of pharmaceutical interest and there is thus a need for new ligands for such receptors. Unfortunately, peptides are not suitable as orally administrated drugs since they are associated with poor absorption, rapid metabolism and low sub-receptor selectivity. One approach that should allow identification of more drug-like ligands is to use the structural information of the endogenous ligand to develop peptidomimetic compounds. The main objective of the work described in this thesis was to convert angiotensin II (Ang II, Asp-Arg-Val-Tyr-Ile-His-Pro-Phe) to small drug-like compounds with retained bioactivity at the AT2 receptor. The study was performed step-wise via incorporation of well-defined secondary structure mimetics and repeated truncation of the peptide. Five scaffolds, comprising a benzene ring as a central element, suitable as a γ-turn or dipeptide mimetics were designed and synthesized. In order to decorate the scaffolds, a method of microwave-assisted alkoxycarbonylation was developed. After incorporation of the scaffolds into Ang II-related peptides or peptide fragments, the affinities for both the AT1 and the AT2 receptor were determined. In the first series of ligands, two tyrosine-related scaffolds were introduced as γ-turn mimetics in Ang II. All five pseudopeptides exhibited good affinities for the AT2 receptor. One compound was chosen for functional studies and was shown to act as an AT2 receptor agonist. After truncation of Ang II it was shown that C-terminal pentapeptide analogs were AT2 receptor selective agonists. A series of pseudopeptides comprising tyrosine-related scaffolds, derived from the pentapeptides, displayed high AT2 receptor affinities. Two compounds had agonistic effect at the AT2 receptor. This study revealed that the N-terminal part was of less importance while a C-terminal Ile residue was a key element for enhanced AT2 receptor affinity. In the final set of compounds, the peptide was truncated to tripeptide C-terminal fragments. After replacing His-Pro by a histidine-related scaffold small drug-like peptidomimetic compounds with nanomolar affinity for the AT2 receptor were identified.

Thèse d'exercice : Pharmacie : Nancy 1 : 2008. / Titre provenant de l'écran-titre.

Submitted by Diogo Misoguti (diogo.misoguti@gmail.com) on 2016-06-29T12:59:34Z No. of bitstreams: 1 cp118956.pdf: 11152798 bytes, checksum: 413c607598471e1abd0db7c49883c8ac (MD5) / Approved for entry into archive by Diogo Misoguti (diogo.misoguti@gmail.com) on 2016-06-29T13:00:23Z (GMT) No. of bitstreams: 1 cp118956.pdf: 11152798 bytes, checksum: 413c607598471e1abd0db7c49883c8ac (MD5) / Made available in DSpace on 2016-06-29T13:00:23Z (GMT). No. of bitstreams: 1 cp118956.pdf: 11152798 bytes, checksum: 413c607598471e1abd0db7c49883c8ac (MD5) Previous issue date: 2009 / Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) / Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) / Com o crescente aumento da prevalência mundial de diabetes mellitus, tem-se buscado modelos experimentais para melhor compreensão de sua fisiopatologia e tratamento que atendam de maneira mais adequada à preservação de células beta, proteção de órgãos-alvo e atenuação da aterosclerose. Objetivos: Desenvolver modelo experimental de diabetes mellitus tipo 2 induzido por meio de dieta, e utilizá-lo para examinar os efeitos de um inibidor da enzima conversora de angiotensina (IECA) e de um bloqueador do receptor de angiotensina (BRA) na proteção de órgãos-alvo. Métodos: Coelhos machos Nova Zelândia (n=49) receberam dieta acrescida de banha (10%), sacarose (40%) durante todo o protocolo do estudo além de colesterol (0,5% nos três primeiros meses e 0,1% nos meses subseqüentes). Os animais receberam aleatoriamente: apenas a dieta sem fármacos (G1), olmesartana 5 mg (G2), quinapril 30 mg (G3), ou a combinação de ambos (G4), acrescidos à mesma dieta por seis meses. Foram analisados lípides, frutosamina, glicose e insulina em jejum com cálculo dos índices para resistência à insulina e função de células beta pancreáticas. Foram ainda examinadas as áreas sob as curvas de insulina e glicose, após infusão de glicose intraperitoneal. Angiofluoresceinografias e análises histopatológicas avaliaram lesões em órgãos-alvo. Resultados: Os coelhos ganharam peso, e houve aumento dos níveis de glicose, colesterol total, LDL-C e triglicérides e redução do HDL-C (p <0,05 vs. basal). A frutosamina e o HOMA-IR se elevaram, enquanto houve redução do HOMA-β (p <0,05 vs. basal). Sinais precoces de retinopatia diabética foram observados a partir do terceiro mês, progredindo até o final do experimento (p<0,0005). Lesões ateroscleróticas em aorta, esteatofibrose hepática e infiltrado glomerular de macrófagos constituíram os principais achados histomorfológicos. O bloqueio do sistema renina-angiotensina modificou favoravelmente a glicemia e o HOMA-β (p<0,05) e houve atenuação do número e grau dos microaneurismas pelo tratamento com BRA isoladamente ou combinado com IECA (p<0,05 vs. G1). Conclusões: Nosso modelo reproduziu várias características glucometabólicas do diabetes mellitus tipo 2 humanóide, incluindo déficit de secreção e resistência à insulina. O bloqueio do sistema renina-angiotensina atenuou algumas alterações bioquímicas e as lesões microvasculares em retina. / With the increasing prevalence of diabetes mellitus worldwide, new experimental models are required to better understand the pathophysiology of this disease and to offer therapeutic options that can preserve pancreatic beta-cells, protect target organs and attenuate atherosclerosis. Objective: The aims of this study were to develop an experimental model of type 2 diabetes mellitus induced by diet and assess on this model the effects of an angiotensin-converting enzyme inhibitor (ACEI) and an antagonist of the angiotensin II type1 receptor (AT1R) on target organ protection. Methods: New Zealand male white rabbits (n=49) were fed high-fat/high-sucrose (10/40%) during the study protocol and cholesterol-enriched diet (0.5% in the first three months followed by 0.1% until the end of the study). These animals were randomized to receive: diet alone (G1), olmesartan 5 mg (G2), quinapril 30mg (G3), or combination of both drugs (G4), added to the same diet for six months. Fasting lipids, fructosamine, glucose and insulin, with calculation of insulin resistance and beta-cell function indexes were evaluated. The areas under the curves for glucose and insulin were obtained after intraperitoneal glucose bolus injection. Fluorescein angiography and histopathological analyses were performed to assess target-organs lesions. Results: The animals gained weight, and there were increases in blood glucose, total cholesterol, LDL-C and triglycerides, and decrease in HDL-C (p<0.05 vs. baseline). Fructosamine levels and the homeostasis model assessment of insulin resistance (HOMA-IR) were increased, while there was a reduction in the HOMA-β (p<0.05 vs. baseline). Early clinical features of diabetic retinopathy were seen since the third month, progressing up to the end of the experiment (p<0.0005). Aortic atherosclerosis, hepatic steatofibrosis and glomerular macrophage infiltration were the main histomorphologic findings of this study. The renin-angiotensin system (RAS) blockade favorably modified blood glucose and the HOMA- β (p<0.05) and promoted attenuation of the number and grade of microaneurysms in retina in the group of animals receiving AT1R antagonist or combined therapy with the ACEI (p<0.05 vs. G1). Conclusion: Our model reproduced several glucometabolic characteristics of humanoid type 2 diabetes, including decreased insulin secretion and insulin resistance. The RAS blockade attenuated some biochemical abnormalities and the diabetic retinopathy. / FAPESP: 07/51058-8

A hipótese do estudo é a de que a Angiotensina II (AngII) é capaz de desencadear processos inflamatórios iniciais que compõem parte dos mecanismos envolvidos na lesão vascular ou no seu progresso. Os objetivos foram avaliar a expressão de marcadores iniciais de inflamação em resposta à ação da AngII e por qual receptor (AT1 ou AT2) esta levaria à expressão destes marcadores inflamatórios. O estudo foi realizado em camundongos machos C57Bl/6J submetidos ao tratamento com doses subpressoras de AngII, bloqueadores dos receptores AT1 e AT2 e uma combinação destes. Os tempos de tratamento foram determinados através de uma curva de tempo-resposta feita com injeções de AngII. Após definição da curva temporal foram preparados 6 grupos de animais: controle, tratados AngII, Losartan, AngII+Losartan, PD123319 e AngII+PD123319. Foram feitas avaliações dos marcadores inflamatórios nos corações por imunohistoquímica para citocinas IL-1<font face=\"Symbol\">b e IL-6, TNF<font face=\"Symbol\">a, TGF-<font face=\"Symbol\">b e MCP-1, a molécula de adesão ICAM-1, e foram quantificados a IL-6 e o TNF-<font face=\"Symbol\">a séricos pela técnica ELISA. / The study hypothesis is that the angiotensin II (Ang II) is capable of triggering inflammatory processes that comprise the initial part of the mechanisms involved in vascular injury or in progress. The objectives were to evaluate the expression of early markers of inflammation in response to the action of Ang II and which receptor (AT1 and AT2) this would lead to the expression of these inflammatory markers. The study was conducted in male C57Bl/6J mice undergoing treatment with subpressor doses of AngII, blockers of AT1 and AT2 receptors and a combination thereof. Treatment times were determined using a time-response curve performed with injections of AngII. After definition of time curve were prepared six animal groups: control, treated Ang II, losartan, Ang II + losartan, PD123319 and Ang II + PD123319. Evaluations were made in the hearts of inflammatory markers by immunohistochemistry for IL-1<font face=\"Symbol\">b and IL-6, TNF<font face=\"Symbol\">a, TGF-<font face=\"Symbol\">b and MCP-1, the adhesion TNF-<font face=\"Symbol\">a serum by ELISA.

Neuropathic pain is one of the most debilitating disorders. Currently available treatments for neuropathic pain are still unsatisfactory as they have only limited treatment effect and patients may suffer from unwanted side effects. Mechanism-based approaches to neuropathic pain treatment are considered to be more effective. Therefore multiple studies are dedicated to study the pathophysiological mechanisms of neuropathic pain. One of the possible underlying mechanism that causes neuropathic pain is neuroinflammation. Recent studies suggested that angiotensin II ( main effector molecule of the renin-angiotensin system) via its receptors in the central nervous system may be involved in the neuroinflammatory processes. The aim of this study was to investigate the role of angiotensin receptor type 1 in the developement and maintenance of neuropathic pain induced in animal model. Spinal nerve ligation (L5) was used as a model of peripheral neuropathy. Our results showed that treatment with AT1R blocker losartan markedly reduced thermal hyperalgesia and reduced increased sensitivity to mechanical stimuli in the SNL-operated rats.This indicates a possibly significant role of AT1 receptors in the development of neuropathic pain, probably due to reduction of neuroinflammation in the nervous system. These findings...

This research investigates to what extent the ARCH model and the GARCH model forecasts one-day-ahead out-of-sample daily volatility (conditional variance) in European AT1 CoCo bonds compared to the Random Walk model. The research also investigates how different orders of ARCH and GARCH models affect the forecasting accuracy. Specifically, the models investigated are the Random Walk model, ARCH(1), ARCH(2), ARCH(3), GARCH(1,1), GARCH(1,2), GARCH(2,1), and the GARCH(2,2)model. The data set used in this report is 47 European AT1 CoCo bonds from 20 different issuers.The results show that 42 out of 47 CoCo bonds have daily log returns that are conditional heteroscedastic. Five CoCo bonds with homoscedastic daily log returns were CoCo bonds with significant low liquidity. The results show that the GARCH model outperforms both the Random Walk model and the ARCH model, under the assumption that the innovations follow a normal distribution. The results also show that a higherorder of ARCH or GARCH does not necessarily lead to more accurate forecasts. The GARCH(1,1) model provided the most accurate predictions. The conclusion is that the GARCH models provide accurate volatility forecasts in CoCo bonds compared to the ARCH-model, and the Random Walk model. However, the ARCH model and the GARCH model fail to forecast the daily volatility in CoCo bondswith insufficient liquidity. Furthermore, a higher order of ARCH or GARCH models does not necessarily lead to better forecast results. / Denna uppsats undersöker till vilken utsträckning som ARCH och GARCH-modeller kan prediktera daglig volatilitet i AT1 CoCo-obligationer (eng. Additional Tier-1 Contingent Convertible Bonds), jämfört med Random Walk-modellen. Uppsatsen undersöker även hur olika parametrar I ARCH och GARCH-modeller påverkar resultatet i prediktionerna. De modeller som undersöks är Random Walk-modellen, ARCH(1), ARCH(2), ARCH(3), GARCH(1,1), GARCH(1,2), GARCH(2,1), och GARCH(2,2)-modellen. Datasetet som har använts i denna forskning består av 47 Europeiska AT1 CoCo obligationer från 20 olika emittenter. Resultatet visar att 42 av 47 CoCo-obligationer har betingat heteroskedastisk daglig avkastningsdata. Fem CoCo-obligationer med homoskedastisk avkastningsdata är obligationer med signifikant låg likviditet. Vidare visar resultatet visar att GARCH modellen överpresterar jämfört med både Random Walk-modellen och ARCH-modellen, under antagandet att innovationstermen följer en normal distribution. Resultatet visar även att en högre ordning av ARCH eller GARCH inte nödvändigtvis leder till ett bättre resultat i prediktonerna. GARCH(1,1)-modellen är modellen som predikterar den dagliga volatiliten i CoCo-obligationerna med bäst resultat. Slutsatsen är att GARCH-modellen predikterar volatiliteten i CoCo-obligationer bättre jämfört med ARCH-modellen och Random Walk-modellen. Däremot kan inte ARCH-modellen eller GARCH-modellen modellera CoCo-obligationer med signifikant låg likviditet. Vidare så medför en högre ordning i ARCH eller GARCH-modellen inte nödvändigtvis till bättre prediktioner.